Lonafarnib
- TRADE NAMES: SCH 663366; Zokinvy (Eiger Biopharmaceuticals)
- INDICATIONS:
Reduction of the risk of mortality in Hutchinson-Gilford Progeria Syndrome. For treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations.
- CLASS: Farnesyltransferase inhibitor
- HALF-LIFE: approximately 4–6 hours
FDA APPROVAL DATE: 11/20/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Atorvastatin, CYP2C9 inhibitors, CYP3A inducers, CYP3A inhibitors, Grapefruit Juice, Loperamide, Lovastatin, Midazolam, Simvastatin
Can cause fetal harm. Advise females of reproductive potential of the risk to a fetus and to use effective contraception.
Based on animal studies, may impair fertility. Advise females and males of the adverse reproductive potential of lonafarnib.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric